Back to Journals » Research and Reports in Urology » Volume 3

Update on the management of overactive bladder: patient considerations and adherence

Authors Gomelsky A, Dmochowski R

Published 30 December 2010 Volume 2011:3 Pages 7—17

DOI https://doi.org/10.2147/RRU.S7233

Review by Single-blind

Peer reviewer comments 2


Alex Gomelsky1, Roger R Dmochowski2
1Department of Urology, Louisiana State University Health Sciences Center – Shreveport, Shreveport, LA, USA; 2Department of Urologic Surgery, Vanderbilt University Medical Center, Nashville, TN, USA

Abstract: Overactive bladder (OAB) is a common condition that causes a profound impact on an individual’s overall health and quality of life. Muscarinic receptor antagonists are the mainstay of oral pharmacotherapy for OAB. Although all of the medications in this class are significantly more effective than placebo, they are also associated with more adverse events that may limit their overall use. Although newer preparations of these medications have sought to improve tolerability and efficacy through alternative routes of delivery and once-daily dosing, improved adherence to treatment and treatment persistence continue to be an ongoing challenge. An improved understanding of the factors involved in persistence of medical OAB therapy is imperative in efforts to optimize therapeutic benefits in this chronic and potentially morbid condition.

Keywords: adherence, overactive bladder, antimuscarinic receptor antagonists

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]